c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 144 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SGX-523
CAS:SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
Fórmula:C18H13N7SPureza:99% - >99.99%Cor e Forma:SolidPeso molecular:359.41BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Cor e Forma:SolidPeso molecular:468.84Pamufetinib mesylate
CAS:Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Fórmula:C28H27FN4O7S2Pureza:98.91%Cor e Forma:SolidPeso molecular:614.67XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Fórmula:C29H25FN4O5Pureza:98.60%Cor e Forma:SolidPeso molecular:528.53Crizotinib hydrochloride
CAS:Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Fórmula:C21H23Cl3FN5OPureza:98.73% - 98.87%Cor e Forma:SolidPeso molecular:486.8Ref: TM-T8399
5mg34,00€10mg50,00€25mg78,00€50mg94,00€100mg131,00€200mg162,00€500mg215,00€1mL*10mM (DMSO)56,00€BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Fórmula:C25H16F2N4O3Pureza:98.33%Cor e Forma:SolidPeso molecular:458.42Ref: TM-T8326
1mg67,00€2mg88,00€5mg148,00€10mg230,00€25mg430,00€50mg622,00€100mg898,00€1mL*10mM (DMSO)170,00€Foretinib phosphate
CAS:Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Fórmula:C34H40F2N4O14P2Cor e Forma:SolidPeso molecular:828.65Amuvatinib
CAS:Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.Fórmula:C23H21N5O3SPureza:99.38% - >99.99%Cor e Forma:SolidPeso molecular:447.51PHA-665752
CAS:PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Fórmula:C32H34Cl2N4O4SPureza:97.05% - 98.82%Cor e Forma:SolidPeso molecular:641.61Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H17FN6OPureza:99.24%Cor e Forma:SolidPeso molecular:412.42Ref: TM-T1963
5mg48,00€10mg63,00€25mg78,00€50mg90,00€100mg124,00€200mg158,00€500mg255,00€1mL*10mM (DMSO)50,00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Fórmula:C19H16N8OPureza:98.41% - 98.55%Cor e Forma:SolidPeso molecular:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Fórmula:C25H23FN8O2S2·HClPureza:97.95%Cor e Forma:SolidPeso molecular:587Ref: TM-T5677
1mg35,00€5mg57,00€10mg95,00€25mg178,00€50mg264,00€100mg374,00€200mg537,00€1mL*10mM (DMSO)96,00€S49076 HCl
CAS:S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Fórmula:C22H18ClN3O5Pureza:98%Cor e Forma:SolidPeso molecular:439.85JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Fórmula:C19H13F2N7Pureza:97.15% - 98.61%Cor e Forma:SolidPeso molecular:377.35SGI-7079
CAS:SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.Fórmula:C26H26FN7Pureza:95.51% - 99.26%Cor e Forma:SolidPeso molecular:455.53Ref: TM-T6982
2mg39,00€5mg58,00€10mg92,00€25mg178,00€50mg230,00€100mg334,00€500mg782,00€1mL*10mM (DMSO)64,00€RPI-1
CAS:RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.Fórmula:C17H15NO4Pureza:98.91% - ≥95%Cor e Forma:SolidPeso molecular:297.31Merestinib
CAS:Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Fórmula:C30H22F2N6O3Pureza:95% - 99.71%Cor e Forma:SolidPeso molecular:552.53Ref: TM-T3455
1mg50,00€2mg66,00€5mg100,00€10mg137,00€25mg240,00€50mg403,00€100mg573,00€500mg1.198,00€1mL*10mM (DMSO)119,00€MGCD-265 analog
CAS:Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Fórmula:C26H20FN5O2S2Pureza:98.06% - 98.68%Cor e Forma:SolidPeso molecular:517.6Ref: TM-T6351
2mg35,00€5mg52,00€10mg85,00€25mg164,00€50mg255,00€100mgA consultar1mL*10mM (DMSO)62,00€Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Fórmula:C17H15N9Pureza:98.12%Cor e Forma:SolidPeso molecular:345.36Ref: TM-TQ0210
1mg47,00€2mg60,00€5mg96,00€10mg124,00€25mg200,00€50mg353,00€100mg537,00€1mL*10mM (DMSO)92,00€Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Fórmula:C23H18ClFN6OPureza:98.62% - 99.81%Cor e Forma:SolidPeso molecular:448.89
